SlideShare una empresa de Scribd logo
1 de 14
Descargar para leer sin conexión
19/04/2016
1
Precision medicine:
tailoring COPD management to specific
patient needs, phenotypespat e t eeds, p e otypes
Alan Kaplan MD CCFP(EM) FCFP
Chairperson Family Physician Airways Group of Canada
Conflicts: Advisory Board or speakers bureau for 
Astra Zeneca, Boehringer Ingelheim, Novartis, Takeda, 
Merck Frosst, Pfizer, Purdue
1
Objectives
• Review current guidelines for COPD pharmacotherapy
• Review how to tailor our pharmacotherapy to those who 
will best benefit from them
– Personalized care vs guideline care
oror
– How to use guidelines in the patient in front of you
• Discuss how to fix it when therapy is perhaps..not as 
optimized as it could be!
2
I am not going to talk about
• Making an early diagnosis
• Smoking cessation
• Pulmonary Rehabilitation
• Oxygen therapy
• End of life therapy in COPD
• Multimorbitidity
3
Nice overview to make you consider
the individual patient in front of you
4
19/04/2016
2
TREATABLE TRAITS
(can coexist)
IMP RE
C
DIAGNOSTIC
CRITERIA
TREATMENT MAIN
EXPECTE
D
BENEFIT
First choice Efficacy Second choice*
Airflow limitation +++ +++ FEV1/FVC < 0.7 (or
LLN)
S
Airway smooth
muscle contraction
++ +++ BD Reversibility, PEF
variability, positive PC20
Maintenance: LABA
and/or LAMA
Rescue: SABA or
SAMA
+++ ICS
Bronchial Thermoplastya
S
Loss of elastic recoil
(Emphysema )
+++ ++ CT, DLCO, compliance Smoking cessation + LVRS, Lung transplantation,
a1anti-trypsin replacement if
deficient. Valves, coils
S,P
Airway mucosal
oedema
++ + CT. Spirometry-induced
bronchoconstriction.
ICS ++ OCS. Anti-IL5, IL13, IL4 E
Eosinophilic airway +++ +++ Sputum eos, blood eos, ICS +++ OCS, LTRA, Anti-IgE, Anti- E
Table 1. Pulmonary treatable traits of airway diseases
5
Eosinophilic airway
inflammation (EAI)
Sputum eos, blood eos,
FENO, (periostin)
ICS OCS, LTRA, Anti IgE, Anti
IL5, IL13, IL4
E
Chronic bronchitis ++ +++ Cough and sputum 3
months x 2 yrs. (no EAI)
Smoking cessation + Carbocysteine, macrolides,
roflumilast
E
Airway bacterial
colonization*
++ ++ Sputum culture,
quantitative PCR
Antibiotics ++ Long-term low dose
macrolides, vaccination
E/S
Bronchiectasis* ++ ++ CT Drainage + Macrolides, Nebulized
Antibiotics, Surgery,
Vaccination
E/S
Cough reflex hyper-
sensitivity
++ +++ Capsaicin challenge,
cough counts, cough
questionnaire.
Speech and language
treatment (63)
+ Gabapentin (62)
.
S
Pre-capillary
pulmonary
hypertension*
++ ++ Doppler
echocardiography, BNP
Right-heart
catheterization
LTOT ++ NIV
Lung transplantation
S,E,P
Chronic respiratory
failure*
Arterial hypoxemia +++ +++ PaO2<55 mmHg LTOT ++ P
Arterial hypercapnia +++ +++ PaCO2>45 mmHg + NIV Agusti A et al. 2015
TREATABLE
TRAITS
(can coexist)
IMP RE
C
DIAGNOSTIC
CRITERIA
TREATMENT MAIN
EXPECT
ED
BENEFIT
First choice Efficacy Second choice*
Deconditioning + + CPET, 6MWD Exercise,
rehabilitation
+ S,P
Obesity + +++ BMI Diet, Physical activity + Medication, Bariatric
surgery
S,P
Cachexia + +++ BMI Diet, Physical activity + S, E
OSAS + ++ Questionnaires, PSG CPAP + Weight loss. Mandibular
advancement splint
S,P
Cardiovascular
disease
++ +++ EKG, Doppler
Echocardiography,
BNP
ACE inhibitors,
diuretics,
b-Blockers
++ Surgery S,E,P
GERD (64) + ++ GI endoscopy pH PPI, H2 antagonist + Surgery S
Table 2. Extra-pulmonary treatable traits of airways diseases
6
GERD (64) GI endoscopy, pH
monitoring
PPI, H2 antagonist Surgery S
Upper airway
diseases rhino-
sinusitis
+ ++ History and
examination, imaging
Topical steroids ++ LTRA, antihistamines,
surgery
S, E
Upper airway
diseases
Inducible laryngeal
obstruction (vocal
cord dysfunction)
++ + Fibreoptic
laryngoscopy, flow-
volume curve, dynamic
CT neck
Speech pathology
therapy (63)
++ Laryngeal botulinum toxin
Psychology/psychiatry
S
Psychiatric
disorders:
depression
++ ++ Questionnaires,
psychologist/liaison
psychiatrist
assessment
CBT,
pharmacotherapy
++ S
Psychiatric
disorders
Anxiety:
Anxiety/other
behavioural aspects
including breathing
++ ++ Questionnaires,
psychologist/liaison
psychiatrist
assessment
Anxiety
management,
breathing retraining
+ Anxiolytic/antidepressant
medication, CBT,
Psychotherapy
S
Agusti A et al. 2015
7 8
19/04/2016
3
Let’s deal with two scenarios
1) The patient with recurrent
exacerbations
2) The returning patient on therapy
9
Case 1
• 67 year old woman with established COPD
• No longer golfing due to dyspnea
• On LABA/LAMA plus SABA for breakthrough
• FEV1 40%
• CAT score 15
• Says, ‘I am doing fine’
• Averages two exacerbations yearly, admitted last year once
• You have done all the other little things: CV protection, osteoporosis
screening, mood is ok, weight is stable, referred for pulmonary
rehabilitation
• Is she fine?
• How do you decide?
10
What are your options (for exacerbation
prevention)?
• Add ICS to LABA/LAMA
• Change to ICS/LABA plus LAMA
• Add Roflumilast to LABA/LAMA
f CS/• Add Roflumilast to LAMA plus ICS/LABA
11
Based on combined assessment of airflow limitation, symptoms and exacerbation risk
Exacerb
cationof
ation
(FEV1 < 30%
predicted)
(30% ≤ FEV1 <
50% predicted)
GOLD Group C
ICS + LABA, or LAMA ICS + LABA +/or LAMA
Recommended first choice
GOLD Group D
≥2
or
≥1 leading to
hospital
admission
GOLD Grade 4
LAMA + LABA or
LAMA + PDE-4i or
LABA + PDE-4i
ICS + LABA + LAMA or
ICS + LABA + PDE-4i or
LAMA + LABA or
LAMA + PDE-4i
Alternative choice
Pharmacologic management of COPD
GOLD 2015
GOLD Grade 3
12
Risk
bationhistory
Risk
GOLDclassific
airflowlimit
(50% ≤ FEV1 <
80% predicted)
(FEV1 ≥ 80%
predicted)
LAMA or LABASAMA or SABA p.r.n.
GOLD Group A GOLD Group B
1 (not leading
to hospital
admission)
Symptoms
CAT ≥10CAT <10
mMRC 01 mMRC ≥2
Breathlessness
LAMA or
LABA or
SABA + SAMA
LAMA + LABA
GOLD 2015
CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
HRQoL, health-related quality of life; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC,
modified Medical Research Council; PDE-4i, phosphodiesterase type 4 inhibitor; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic
antagonist
GOLD Grade 2
GOLD Grade 1
19/04/2016
4
CTS/CHEST Guidelines: AECOPD
EVEN EASIER, RIGHT?
2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of Chronic Obstructive Pulmonary
Di
COPD Exacerbations: Effects of ICS  
(ISOLDE ‐ stratified by FEV1)
2.64
1.86
1.722.0
2.5
3.0
*
*
Placebo
r year)
Fluticasone
1.24
1.41
1.24
0.0
0.5
1.0
1.5
Burge et al. Br Med J. 2000; 320:1297-1303.
FEV1 (litres)
Exacerbations (pe
1.25 ‐ 1.54 >1.54<1.25
14
Impact of ICS on survival without re‐
hospitalisation
• Alberta
• 6,740 patients
• Aged > 65 yrs
ICS 29%
ehospitalisation
1.0
0.9
0 8
Inhaled steroids
Sin DD & Tu JV, AJRCCM 2001; 164: 580-584
• ICS group: 29%
relative risk reduction
for all-cause mortality
and 24% for
re-hospitalisation
Survivalwithoutre
Time from discharge (months)
0.8
0.7
0.6
No inhaled steroids
0 2 4 6 8 10 12
15
TORCH: LABA/ICS Significantly Reduced Rate of 
Exacerbations Over 3 Years
exacerbations/year
1.13
0.97*
0.93*
0.85*†‡
SALM/FP
25% reduction
in exacerbations
vs. placebo
0.8
1
1.2
LABA: Long-acting beta2-agonist ; ICS: inhaled corticosteroid
SALM: salmeterol; FP: fluticasone propionate
SALM/FP: salmeterol/fluticasone propionate
*P < 0.001 vs. placebo †P =0.002 vs. SALM ‡P = 0.024 vs. FP
Meannumberofe
0
0.2
0.4
0.6
Placebo SALM FP SALM/FP
Treatment
Adapted from Calverley PM, et al. N Engl J Med. 2007;356:775-789. 16
19/04/2016
5
0.4
0.3
0.2
erbations/patient
TIO + budesonide/formoterol 320/9 µg BID
TIO + placebo
CLIMB: ICS/LABA + Tiotropium Reduced Severe
Exacerbations at 3 Months
A reduction in rate of
exacerbation by 62%
17
0.1
0.0
0 15 30 45 60 75 90
Days since randomisation
Exac
Ratio: 0.38 (95% CI: 0.25–0.57)
P < 0.001*
*Poisson regression
adjusted for
overdispersionSevere exacerbations were defined as worsening of COPD leading to treatment
with systemic steroids (oral or parenteral) and/or hospitalization/emergency room
visits.
Welte T, et al. Am J Respir Crit Care Med 2009; doi:10.1164/rccm.200904-0492OC.
Goal: prevent exacerbations
Goal: decrease symptoms
Bronchodilate!!!
Cough and Sputum: One of the Susceptible
Phenotypes for COPD Exacerbators
*
* p<0.0001
erbationsPerYear
19
Percentwith≥2Exac
Burgel P-R, et al. Chest. 2009;135:975-982.
How about Roflumilast
Proportion of Patients with a Moderate or Severe
Exacerbation
sal or tio + placebo sal or tio + roflumilast 500 µg
20
16
12
acerbation (%)
16
1111
18
Exacerbation rates were based on a Poisson regression model;
Risk ratios (RiR) were based on a log binomial regression model
Fabbri LM, et al. Lancet. 2009 Aug 29;374(9691):695-703.
n = 83/467 n = 51/466 n = 58/372 n = 42/371
RiR = 0.60
(95% CI 0.43, 0.82)
p = 0.0015
RiR = 0.73
(95% CI 0.51, 1.05)
p = 0.0867
Salmeterol study Tiotropium study
12
8
4
0
n=83/467 n=51/466 n=58/372 n=42/371
Patients with an exa
1111
19/04/2016
6
0.60
1.0
REACT – reduction in rate of severe exacerbations
(i.e. events leading to hospitalization and/or death)
Adding Roflumilast to triple therapy
∆ = -24.3%
Rate ratio = 0.757
CI: 0.601, 0.952
p=0.018
All patients
Patients with a
prior hospitalization
Patients without a
prior hospitalization
∆ = -34.9%
Rate ratio = 0.651
CI: 0.477, 0.887
p=0.007
∆ = -7.6%
Rate ratio = 0.924
CI: 0.669, 1.278
p=0.634
cerbationsper
eryear
0.32
0.18
0.24
0.39
0.17
0
0.5
N=319      N=322 N=647     N=647
Analysis of rate of severe exacerbations per patient
per year using a negative binomial regression model, ITT
Martinez FJ, et al. Presented at ERS 2015; OA482
Martinez FJ, et al. Lancet 2015;385:857-66.
Placebo + LABA/ICS
Roflumilast + LABA/ICS
N=966 N=969
NNT = 12.5 NNT = 4.8 NNT = 100.0
Meanrateofexac
patientpe
Roflumilast: Incidence of AEs
( 2.5%)*
Adverse Event
AURA/HERMES
1 year
HELIOS
6 months
Roflumilast
(n=1547)
Placebo
(n=1545)
Tiotropium +
Roflumilast
(n=374)
Tiotropium +
Placebo
(n=369)
COPD 10% 13% 16% 19%
Weight loss 10% 3% 6% <1%
Diarrhea 8% 3% 9% <1%
Nasopharyngiti
s
6% 6% 6% 5%
Nausea 4% 2% 3% 1%
Bronchitis 4% 4% 2% 3%
Headache 3% 2% 2% 0%
Back pain 3% 2% 2% 1%
*Independent of investigator causality assessments
Calverley PM, et al. Lancet. 2009 Aug 29; 374(9691):685-94.
Fabbri LM, et al. Lancet. 2009 Aug 29;374(9691):695-703.
So, where are we?
• Tailor our therapy to our patient
• Bronchodilate aggressively to improve functionality
• Anti-inflammatory to help prevent exacerbations
• Reassess over time
• But what is the real life situation?
• In Canada/ most of the world, there are a large number of patients
with COPD currently on ICS!
23
ICS use in COPD (Real life data in Canada)
Reza Maleki-Yazdi M. et al. ATS 2015, P551 024
19/04/2016
7
So, where are we?
• Tailor our therapy to our patient
• Bronchodilate aggressively to improve functionality
• Anti-inflammatory to help prevent exacerbations
• Reassess over time
• But what is the real life situation?
• In Canada/ most of the world, there are a large number of patients
with COPD currently on ICS!
• Do ICS decrease COPD mortality??
25
TORCH: All‐Cause Mortality at 3 Years
18
16
14
12
10
ofdeath(%)
SALM/FP
17.5% reduction
in mortality vs
placebo
(p=0.052)
No significant
difference of
mortality with ICS
SALM = salmeterol
FP = fluticasone propionate
SALM/FP = salmeterol/fluticasone propionate
8
6
4
2
0
Time to death (weeks)
Probabilityo
0 12 24 36 48 60 72 84 96 108 120 132 144 156
Vertical bars are standard errors
SALM
SALM/FP
FP
Placebo
Adapted from Calverley PMA, et al. N Engl J Med. 2007;356. 26
Case 2
• A different patient with COPD
• FEV1 45%
• No exacerbations needing steroids in five years
• Couple of antibiotics for Sinusitis, did not move into their chest
• CAT score: 18
• On triple therapy: ICS/LABA and LAMA
• Does this patient need their ICS?
• Can you stop it?
• If so, how to stop it?
28
19/04/2016
8
Side effects of ICS in COPD 
and type of evidence 
Randomised
controlled trial
Observational
study
Systematic
review
Pneumonia X X X
Tuberculosis X
Bone fracture
(no effect on
fracture risk)
X X
fracture risk)
Skin thinning/
easy bruising
X
Cataract X
Diabetes X
Oropharyngeal
candidiasis
X X X
Price D. Prim Care Respir J 2013; 22: 92-100. 29
Risk of Diabetes1 Risk of Bone Fracture2
3.5
3.0
2.5
atio
2 Loke YK et al Thorax 2011;66(8):699-708
31
Meta-analysis of studies including
17,513 patients with COPD
2.0
1.5
1.0
0.5
0 250 500 750 10001250 1500 17502000
Daily dose in fluticasone equivalents (mcg)
Rate Ra
1. Suissa S, et al.: Am J Med 2010; 123(11):1001‐6. 
Several recent studies with varying populations/design
have compared bronchodilator therapy with LABA/ICS
OPTIMO – in patients with moderate COPD (FEV1 >50% predicted) and <2 exacerbations,
currently maintained on ICS for past year, ICS withdrawal was not associated with increased
exacerbations, difference in lung function or CAT
(Rossi, et. al. Resp Res 2014; 6 month “real-world” study of ICS withdrawal - decision to maintain or withdraw ICS at discretion of
clinician)
INSTEAD – in patients with moderate COPD (FEV1 40-80% predicted) and no recent
exacerbations, maintained on SFC for > 3 months, indacaterol was NI on lung function
(t h FEV1 9 l) d id f i d b ti(trough FEV1 = -9 ml) and no evidence of increased exacerbations
(Rossi, et. al. ERJ 2014; 26 week randomized, parallel, DB study of withdrawal of ICS from SFC 500/50 to Indacaterol 150 µg)
ILLUMINATE - in patients with moderate COPD (FEV1 40-80% predicted) and no recent
exacerbations, QVA (LABA/LAMA) improved lung function (FEV1AUC0-12 138ml, p<0.001) and
TDI vs LABA/ICS
(Vogelmeier, et. al. Lancet Resp Med 2012, 26 week randomized, parallel, DB study of QVA149 vs SFC 500/50)
LANTERN- in symptomatic patients with moderate to severe COPD (FEV1 30-80) and 0-1
exacerbations on SFC changed to QVA (LABA/LAMA) showed improved lung function
(FEV1 AUC0-4h 122 mL; p<0.001) and decreased exacerbations (HR 0.65 p .028)
(Zhong et al. Int J COPD 2015. A randomized control study of QVA 149 vs SFC)32
19/04/2016
9
Wisdom
Estimated probability of moderate or severe
COPD exacerbation
0.6
0.4
tedprobability
0.3
0.5
Hazard ratio, 1.06 (95% CI, 0.94–1.19)
P=0.35 by Wald’s chi-squared test
1243
1242
1059
1090
927
965
827
825
763
740
646
646
694
688
615
607
581
570
14
19
No. at risk
ICS
ICS withdrawal
0.2
0.0
0 6 12 18 24 30 36 42 48 54
ICS
ICS withdrawal
Estima
Time to events (weeks)
0.1
Magnussen H et al. N Engl J Med DOI 10.1056/NEJMoal407154
-20
0
0 6 12 18 52
SE)change
FEV1(mL)
Week
ICS
38 mL
100 µg BID 0 µg (placebo)250 µg BID
Mean change from baseline in lung function:
FEV1
ICS withdrawal
-80
-60
-40
Adjustedmean(S
frombaselinein
**p<0.01; ***p<0.0001 vs ICS; restricted maximum likelihood repeated measures model; baseline values 970 mL for ICS, 981 mL for ICS withdrawal
ICS
ICS withdrawal
***
**
1223
1218
1135
1135
1114
1092
1077
1058
970
935
n
ICS withdrawal
ICS
43 mL
Magnussen H et al. N Engl J Med DOI 10.1056/NEJMoal407154
Time to first severe and any severity on-
treatment COPD exacerbation
0.975 1.202 1.482
Time to first severe
COPD exacerbation
36
Hazard ratio
Time to first COPD
exacerbation
(any severity)
On-treatment exacerbations assessed; hazard ratio from Cox proportional hazards
model adjusted for baseline FEV1
Favours ICSFavours withdrawal
Magnussen H et al. N Engl J Med DOI 10.1056/NEJMoal407154
19/04/2016
10
So, definitely not with patients with
Asthma-COPD Overlap Syndrome (ACOS)
• Older patients (≥45 years) with chronic airflow
limitation
• Bronchodilator response (>12%, >400 mL)
but not fully reversiblebut not fully reversible
• Family or personal history of asthma, atopy
or allergic rhinitis
• Asthmatic with smoking history or biomass exposure
Dr. Don Sin. 16th Annual Respiratory Medicine Update, 8 February 2014.
Papaiwannou A, et al. J Thoracic Dis 2014;6(S1):S146-S151.
FLAME: QVA149 vs.SFC in terms of rate of all
COPD exacerbations (mild/moderate/severe) for
52 weeks
• moderate to very severe COPD (GOLD 2011),
• a smoking history of ≥10 pack-years,
• one or more 1 COPD exacerbation requiring systemic
corticosteroids and/or antibiotics in the previous 12 months.38
Initial results: press release
39
Does it depend on the eosinophil?
19/04/2016
11
Changes in post-
bronchodilator FEV1 in
patients with or without
sputum eosinophilia
EV1(L)
0.10
*,#
0.15
*,#
With sputum eosinophilia
Without sputum eosinophilia
SputumSputum eosinophiliaeosinophilia and responseand response toto
budesonidebudesonide in COPD:in COPD:
ICSICS worksworks in COPDin COPD withwith sputumsputum eosinophiliaeosinophilia
Leigh et al. ERJ 2006;27:964-971
∆Post-BDFE
-0.05
0.05
0.00
PrednisoneBudesonidePlacebo
*p<0.05 within group (sputum
eosinophilia) vs placebo
#p<0.05 between groups
If blood eosinophils predict response to ICS, what is the
appropriate cutoff?
42
Do eosinophils predict response to ICS beyond
exacerbations? Chiesi data:
43 | QVA Update | Robert Fogel | Canada Advisory Board, Sep 26, 2015 |Business Use Only | Material ID Code:
19/04/2016
12
Taking patients off ICS in COPD
45
Risk of recurrent pneumonia rises with current ICS use, 
not linked to past ICS use
46
Eurich DT et al. Clin Infect Dis. 2013; 57 (8): 1138-1144
Discontinuation of ICS reduced the risk of
pneumonia associated with long-term ICS
use
Risk of pneumonia following ICS withdrawal
Retrospective analysis using the Quebec health insurance databases for COPD patients discontinued from ICS during
1990-2005 (n=103,386).
COPD=chronic obstructive pulmonary disease; ICS=inhaled corticosteroid.
Suissa S et al. Chest. 2015;148(5):1177-1183.
19/04/2016
13
Are they eligible for ICS withdrawal? If no reason they should stay on ICS...
PREDICTIVE ACCURACY OF PREDICTING
≥ 2 EXACERBATIONS IN OUTCOME YEAR
Daryl Freeman GP Mundesley North Norfolk, 
Clinical Director East of England SCN 
(respiratory).
IMPACT study REG sponsored
Odds ratios for ≥ 2 exacerbations from
logistic regression in patients
with CAT score available (n=3,713)
total population n=3,713 Odds Ratio (95% CI) P-value
Baseline number of exacerbations 1.79 (1.68-1.92) <10-10
19% of patients had ≥ 2 exacerbations
FEV1 % predicted per 10% lower 1.06 (1.01-1.12) 0.02
Female gender 1.32 (1.10-1.58) 0.003
Asthma record ever 1.19 (1.00-1.43) 0.052
Nasal polyps ever 2.02 (1.24-3.29) 0.005
Eosinophilia (≥ 0.5 x 10-9 ) in non-smokers 1.42 (1.03-1.97) 0.03
CAT score per 10 units higher 1.26 (1.14-1.40) 1 x 10--5
19/04/2016
14
There may be other factors we can use
• To predict exacerbations
• To predict response to ICS
• To predict response to stopping ICS
o New REG study being done on those with COPD whoy g
have stopped ICS and outcomes
o -unfortunately, numbers are small in GPRD currently.
What does a personalized COPD
assessment look like?
• Symptoms: CAT, MRC, CCQ
• Are they at risk of attack?
– Previous exacerbations, chronic bronchitis, lung function, GERD
• Lung function
• Still smoking?
• Is there Asthma there? Allergy, rhinitis hx?
• Comorbidities: GERD, Depression, Osteoporosis, Anxiety
• Adherence
– Refill prescription rates
• Inhaler technique
• Pulmonary Rehabilitation
• Biomarkers: eosinophils (blood and sputum), FENO?
• Biologics..coming?
• Self management plan
• Pathway to further treatments: oxygen, LVRT, transplant.EOL care! 54
Thank you for any
thoughts you have about
this study!
www fpagc comwww.fpagc.com
for4kids@gmail.com

Más contenido relacionado

La actualidad más candente

REG Allergy Working Group Meeting
REG Allergy Working Group MeetingREG Allergy Working Group Meeting
REG Allergy Working Group MeetingZoe Mitchell
 
18 aprile 2015 ip malattie reumatiche
18 aprile 2015 ip malattie reumatiche18 aprile 2015 ip malattie reumatiche
18 aprile 2015 ip malattie reumatichePoretti Giovanni
 
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...brnmomentum
 
Systemic corticosteroids in the treatment of acute exacerbations of copd
Systemic corticosteroids in the treatment of acute exacerbations of copdSystemic corticosteroids in the treatment of acute exacerbations of copd
Systemic corticosteroids in the treatment of acute exacerbations of copdChoying Chen
 
Novel strategies to improve diastolic function
Novel strategies to improve diastolic functionNovel strategies to improve diastolic function
Novel strategies to improve diastolic functiondrucsamal
 
Updates On Pharmacological Management Of Stable COPD 2017
Updates On Pharmacological Management Of Stable COPD 2017Updates On Pharmacological Management Of Stable COPD 2017
Updates On Pharmacological Management Of Stable COPD 2017Ashraf ElAdawy
 
Realistic and possible abilities in prevention of COPD exacerbation
Realistic and possible abilities in prevention of COPD exacerbationRealistic and possible abilities in prevention of COPD exacerbation
Realistic and possible abilities in prevention of COPD exacerbationDejan Zujovic
 
Pulmonary complications risk
Pulmonary complications riskPulmonary complications risk
Pulmonary complications riskClaudio Melloni
 
sepsis Source control
sepsis Source control sepsis Source control
sepsis Source control Hossam Afify
 
VAP bundle compliance in ICU - Clinical Audit
VAP bundle compliance in ICU - Clinical AuditVAP bundle compliance in ICU - Clinical Audit
VAP bundle compliance in ICU - Clinical Auditfaheta
 
#Preoperative preparation
#Preoperative preparation#Preoperative preparation
#Preoperative preparationNisar Arain
 
CARDIOLOGIA - Hypertension
CARDIOLOGIA - HypertensionCARDIOLOGIA - Hypertension
CARDIOLOGIA - HypertensionBrunaCares
 

La actualidad más candente (20)

REG Allergy Working Group Meeting
REG Allergy Working Group MeetingREG Allergy Working Group Meeting
REG Allergy Working Group Meeting
 
18 aprile 2015 ip malattie reumatiche
18 aprile 2015 ip malattie reumatiche18 aprile 2015 ip malattie reumatiche
18 aprile 2015 ip malattie reumatiche
 
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
Presentació resultats Estudi multicèntric amb telemedicina Red Promete per pa...
 
Weaning: The art and science
Weaning: The art and scienceWeaning: The art and science
Weaning: The art and science
 
Gold report 2014_jan23
Gold report 2014_jan23Gold report 2014_jan23
Gold report 2014_jan23
 
Inhaled Prostacyclins
Inhaled Prostacyclins  Inhaled Prostacyclins
Inhaled Prostacyclins
 
Systemic corticosteroids in the treatment of acute exacerbations of copd
Systemic corticosteroids in the treatment of acute exacerbations of copdSystemic corticosteroids in the treatment of acute exacerbations of copd
Systemic corticosteroids in the treatment of acute exacerbations of copd
 
Pulmonary Arterial Hypertension Overview for Scleroderma Patients
Pulmonary Arterial Hypertension Overview for Scleroderma PatientsPulmonary Arterial Hypertension Overview for Scleroderma Patients
Pulmonary Arterial Hypertension Overview for Scleroderma Patients
 
Novel strategies to improve diastolic function
Novel strategies to improve diastolic functionNovel strategies to improve diastolic function
Novel strategies to improve diastolic function
 
Updates On Pharmacological Management Of Stable COPD 2017
Updates On Pharmacological Management Of Stable COPD 2017Updates On Pharmacological Management Of Stable COPD 2017
Updates On Pharmacological Management Of Stable COPD 2017
 
Realistic and possible abilities in prevention of COPD exacerbation
Realistic and possible abilities in prevention of COPD exacerbationRealistic and possible abilities in prevention of COPD exacerbation
Realistic and possible abilities in prevention of COPD exacerbation
 
Cap2015
Cap2015Cap2015
Cap2015
 
Pulmonary complications risk
Pulmonary complications riskPulmonary complications risk
Pulmonary complications risk
 
sepsis Source control
sepsis Source control sepsis Source control
sepsis Source control
 
Easl recommendations
Easl recommendationsEasl recommendations
Easl recommendations
 
VAP bundle compliance in ICU - Clinical Audit
VAP bundle compliance in ICU - Clinical AuditVAP bundle compliance in ICU - Clinical Audit
VAP bundle compliance in ICU - Clinical Audit
 
Hepatitis treatment viena
Hepatitis treatment vienaHepatitis treatment viena
Hepatitis treatment viena
 
Obstructive Lung Disease
Obstructive Lung DiseaseObstructive Lung Disease
Obstructive Lung Disease
 
#Preoperative preparation
#Preoperative preparation#Preoperative preparation
#Preoperative preparation
 
CARDIOLOGIA - Hypertension
CARDIOLOGIA - HypertensionCARDIOLOGIA - Hypertension
CARDIOLOGIA - Hypertension
 

Destacado

REG Annual General Meeting 2015
REG Annual General Meeting 2015REG Annual General Meeting 2015
REG Annual General Meeting 2015Zoe Mitchell
 
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCE
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCESNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCE
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCEZoe Mitchell
 
REG Committee Meeting 26/09/15
REG Committee Meeting 26/09/15REG Committee Meeting 26/09/15
REG Committee Meeting 26/09/15Zoe Mitchell
 
REG Biomarkers Working Group Meeting 26/09/15
REG Biomarkers Working Group Meeting 26/09/15REG Biomarkers Working Group Meeting 26/09/15
REG Biomarkers Working Group Meeting 26/09/15Zoe Mitchell
 
REG COPD Control Working Group Meeting 25/9/15
REG COPD Control Working Group Meeting 25/9/15REG COPD Control Working Group Meeting 25/9/15
REG COPD Control Working Group Meeting 25/9/15Zoe Mitchell
 
REG / EAACI Quality Standards Taskforce Meeting
REG / EAACI Quality Standards Taskforce MeetingREG / EAACI Quality Standards Taskforce Meeting
REG / EAACI Quality Standards Taskforce MeetingZoe Mitchell
 
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...Zoe Mitchell
 
REG Cost-Effectiveness Workshop
REG Cost-Effectiveness Workshop REG Cost-Effectiveness Workshop
REG Cost-Effectiveness Workshop Zoe Mitchell
 
Longitudinal Asthma Management Profiles
Longitudinal Asthma Management ProfilesLongitudinal Asthma Management Profiles
Longitudinal Asthma Management ProfilesZoe Mitchell
 
Using CPCSSN Data for Primary Care Research in Canada
Using CPCSSN Data for Primary Care Research in CanadaUsing CPCSSN Data for Primary Care Research in Canada
Using CPCSSN Data for Primary Care Research in CanadaZoe Mitchell
 
Introduction: Maximising the Yield
Introduction: Maximising the YieldIntroduction: Maximising the Yield
Introduction: Maximising the YieldZoe Mitchell
 
REG Child Health Working Group Meeting 26/09/15
REG Child Health Working Group Meeting 26/09/15REG Child Health Working Group Meeting 26/09/15
REG Child Health Working Group Meeting 26/09/15Zoe Mitchell
 
The Epidemiologist's Dream: Denmark
The Epidemiologist's Dream: DenmarkThe Epidemiologist's Dream: Denmark
The Epidemiologist's Dream: DenmarkZoe Mitchell
 
REG Small Airways Study Group Meeting
REG Small Airways Study Group MeetingREG Small Airways Study Group Meeting
REG Small Airways Study Group MeetingZoe Mitchell
 
REG COPD Control Working Group Meeting
REG COPD Control Working Group MeetingREG COPD Control Working Group Meeting
REG COPD Control Working Group MeetingZoe Mitchell
 
REG Collaborators' Meeting
REG Collaborators' MeetingREG Collaborators' Meeting
REG Collaborators' MeetingZoe Mitchell
 
COPD Working Group Meeting
COPD Working Group MeetingCOPD Working Group Meeting
COPD Working Group MeetingZoe Mitchell
 
REG 2015 Winter Summit
REG 2015 Winter SummitREG 2015 Winter Summit
REG 2015 Winter SummitZoe Mitchell
 
Information System for the Enhancement of Research in Primary Care
Information System for the Enhancement of Research in Primary CareInformation System for the Enhancement of Research in Primary Care
Information System for the Enhancement of Research in Primary CareZoe Mitchell
 
REG Collaborators' Meeting 2013
REG Collaborators' Meeting 2013REG Collaborators' Meeting 2013
REG Collaborators' Meeting 2013Zoe Mitchell
 

Destacado (20)

REG Annual General Meeting 2015
REG Annual General Meeting 2015REG Annual General Meeting 2015
REG Annual General Meeting 2015
 
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCE
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCESNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCE
SNIIRAM: PRIMARY AND SECONDARY CARE RESOURCE USE IN FRANCE
 
REG Committee Meeting 26/09/15
REG Committee Meeting 26/09/15REG Committee Meeting 26/09/15
REG Committee Meeting 26/09/15
 
REG Biomarkers Working Group Meeting 26/09/15
REG Biomarkers Working Group Meeting 26/09/15REG Biomarkers Working Group Meeting 26/09/15
REG Biomarkers Working Group Meeting 26/09/15
 
REG COPD Control Working Group Meeting 25/9/15
REG COPD Control Working Group Meeting 25/9/15REG COPD Control Working Group Meeting 25/9/15
REG COPD Control Working Group Meeting 25/9/15
 
REG / EAACI Quality Standards Taskforce Meeting
REG / EAACI Quality Standards Taskforce MeetingREG / EAACI Quality Standards Taskforce Meeting
REG / EAACI Quality Standards Taskforce Meeting
 
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...
Using the right E (Efficacy vs. Effectiveness) in Cost-Effectiveness / Afford...
 
REG Cost-Effectiveness Workshop
REG Cost-Effectiveness Workshop REG Cost-Effectiveness Workshop
REG Cost-Effectiveness Workshop
 
Longitudinal Asthma Management Profiles
Longitudinal Asthma Management ProfilesLongitudinal Asthma Management Profiles
Longitudinal Asthma Management Profiles
 
Using CPCSSN Data for Primary Care Research in Canada
Using CPCSSN Data for Primary Care Research in CanadaUsing CPCSSN Data for Primary Care Research in Canada
Using CPCSSN Data for Primary Care Research in Canada
 
Introduction: Maximising the Yield
Introduction: Maximising the YieldIntroduction: Maximising the Yield
Introduction: Maximising the Yield
 
REG Child Health Working Group Meeting 26/09/15
REG Child Health Working Group Meeting 26/09/15REG Child Health Working Group Meeting 26/09/15
REG Child Health Working Group Meeting 26/09/15
 
The Epidemiologist's Dream: Denmark
The Epidemiologist's Dream: DenmarkThe Epidemiologist's Dream: Denmark
The Epidemiologist's Dream: Denmark
 
REG Small Airways Study Group Meeting
REG Small Airways Study Group MeetingREG Small Airways Study Group Meeting
REG Small Airways Study Group Meeting
 
REG COPD Control Working Group Meeting
REG COPD Control Working Group MeetingREG COPD Control Working Group Meeting
REG COPD Control Working Group Meeting
 
REG Collaborators' Meeting
REG Collaborators' MeetingREG Collaborators' Meeting
REG Collaborators' Meeting
 
COPD Working Group Meeting
COPD Working Group MeetingCOPD Working Group Meeting
COPD Working Group Meeting
 
REG 2015 Winter Summit
REG 2015 Winter SummitREG 2015 Winter Summit
REG 2015 Winter Summit
 
Information System for the Enhancement of Research in Primary Care
Information System for the Enhancement of Research in Primary CareInformation System for the Enhancement of Research in Primary Care
Information System for the Enhancement of Research in Primary Care
 
REG Collaborators' Meeting 2013
REG Collaborators' Meeting 2013REG Collaborators' Meeting 2013
REG Collaborators' Meeting 2013
 

Similar a Utilising real-world evidence to achieve precision medicine in COPD

COPD Translating Guidelines into Clinical Pracice part 2
COPD  Translating Guidelines into Clinical Pracice part 2COPD  Translating Guidelines into Clinical Pracice part 2
COPD Translating Guidelines into Clinical Pracice part 2Ashraf ElAdawy
 
Update on the Management of Pulmonary Hypertension
Update on the Management of Pulmonary HypertensionUpdate on the Management of Pulmonary Hypertension
Update on the Management of Pulmonary HypertensionSarfraz Saleemi
 
COPD Exacerbations: Significance, Assessment, and Current Management
COPD Exacerbations:Significance, Assessment, and Current ManagementCOPD Exacerbations:Significance, Assessment, and Current Management
COPD Exacerbations: Significance, Assessment, and Current ManagementDr.Mahmoud Abbas
 
Copd grading and management guidelines
Copd grading and management guidelinesCopd grading and management guidelines
Copd grading and management guidelinesMaryam Al-Ezairej
 
Treatment strategies for pulmonary hypertension
Treatment strategies for pulmonary hypertensionTreatment strategies for pulmonary hypertension
Treatment strategies for pulmonary hypertensionSarfraz Saleemi
 
The past, present and future of lipid management
The past, present and future of lipid managementThe past, present and future of lipid management
The past, present and future of lipid managementGreg Searles
 
past presnt and futer of dyslidema ttt.pdf
past presnt and futer of dyslidema ttt.pdfpast presnt and futer of dyslidema ttt.pdf
past presnt and futer of dyslidema ttt.pdfAdelSALLAM4
 
COPD GOLD Recommendations
COPD GOLD RecommendationsCOPD GOLD Recommendations
COPD GOLD RecommendationsJillzs
 
Optimising treatment for COPD  ...
 Optimising treatment for COPD                                               ... Optimising treatment for COPD                                               ...
Optimising treatment for COPD  ...Ashraf ElAdawy
 
REG ACOS Working Group Meeting 25/09/15
REG ACOS Working Group Meeting 25/09/15REG ACOS Working Group Meeting 25/09/15
REG ACOS Working Group Meeting 25/09/15Zoe Mitchell
 
Arterial blood gases in ED: Rest in Peace?
Arterial blood gases in ED: Rest in Peace?Arterial blood gases in ED: Rest in Peace?
Arterial blood gases in ED: Rest in Peace?kellyam18
 
Alyn morice hull wsdan 30 june 2011
Alyn morice hull wsdan 30 june 2011Alyn morice hull wsdan 30 june 2011
Alyn morice hull wsdan 30 june 20113GDR
 
Pulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptxPulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptxNannikaPradhan
 
Assessment and management of stable copd
Assessment and management of stable copdAssessment and management of stable copd
Assessment and management of stable copdRashi Vohra
 
ADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENTADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENTdrrajeevsharma7
 

Similar a Utilising real-world evidence to achieve precision medicine in COPD (20)

COPD Translating Guidelines into Clinical Pracice part 2
COPD  Translating Guidelines into Clinical Pracice part 2COPD  Translating Guidelines into Clinical Pracice part 2
COPD Translating Guidelines into Clinical Pracice part 2
 
Update on the Management of Pulmonary Hypertension
Update on the Management of Pulmonary HypertensionUpdate on the Management of Pulmonary Hypertension
Update on the Management of Pulmonary Hypertension
 
COPD Exacerbations: Significance, Assessment, and Current Management
COPD Exacerbations:Significance, Assessment, and Current ManagementCOPD Exacerbations:Significance, Assessment, and Current Management
COPD Exacerbations: Significance, Assessment, and Current Management
 
Copd grading and management guidelines
Copd grading and management guidelinesCopd grading and management guidelines
Copd grading and management guidelines
 
COPD GOLD 2014
COPD GOLD 2014COPD GOLD 2014
COPD GOLD 2014
 
Treatment strategies for pulmonary hypertension
Treatment strategies for pulmonary hypertensionTreatment strategies for pulmonary hypertension
Treatment strategies for pulmonary hypertension
 
The past, present and future of lipid management
The past, present and future of lipid managementThe past, present and future of lipid management
The past, present and future of lipid management
 
past presnt and futer of dyslidema ttt.pdf
past presnt and futer of dyslidema ttt.pdfpast presnt and futer of dyslidema ttt.pdf
past presnt and futer of dyslidema ttt.pdf
 
Epoc
EpocEpoc
Epoc
 
Copd 2006
Copd 2006Copd 2006
Copd 2006
 
COPD GOLD Recommendations
COPD GOLD RecommendationsCOPD GOLD Recommendations
COPD GOLD Recommendations
 
Optimising treatment for COPD  ...
 Optimising treatment for COPD                                               ... Optimising treatment for COPD                                               ...
Optimising treatment for COPD  ...
 
REG ACOS Working Group Meeting 25/09/15
REG ACOS Working Group Meeting 25/09/15REG ACOS Working Group Meeting 25/09/15
REG ACOS Working Group Meeting 25/09/15
 
Arterial blood gases in ED: Rest in Peace?
Arterial blood gases in ED: Rest in Peace?Arterial blood gases in ED: Rest in Peace?
Arterial blood gases in ED: Rest in Peace?
 
Alyn morice hull wsdan 30 june 2011
Alyn morice hull wsdan 30 june 2011Alyn morice hull wsdan 30 june 2011
Alyn morice hull wsdan 30 june 2011
 
Pulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptxPulmonary Arterial Hypetension.pptx
Pulmonary Arterial Hypetension.pptx
 
Assessment and management of stable copd
Assessment and management of stable copdAssessment and management of stable copd
Assessment and management of stable copd
 
ADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENTADVANCES IN PULMONARY HTN TREATMENT
ADVANCES IN PULMONARY HTN TREATMENT
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
stable COPD.pptx
stable COPD.pptxstable COPD.pptx
stable COPD.pptx
 

Más de Zoe Mitchell

ILD Working Group Meeting
ILD Working Group MeetingILD Working Group Meeting
ILD Working Group MeetingZoe Mitchell
 
Databases and Coding Validation Working Group Meeting
Databases and Coding Validation Working Group MeetingDatabases and Coding Validation Working Group Meeting
Databases and Coding Validation Working Group MeetingZoe Mitchell
 
ACOS Working Group Meeting
ACOS Working Group MeetingACOS Working Group Meeting
ACOS Working Group MeetingZoe Mitchell
 
REG IPF / ILD Working Group Meeting
REG IPF / ILD Working Group MeetingREG IPF / ILD Working Group Meeting
REG IPF / ILD Working Group MeetingZoe Mitchell
 
Meeting Report ERS 2013
Meeting Report ERS 2013 Meeting Report ERS 2013
Meeting Report ERS 2013 Zoe Mitchell
 
Real Time Research in a Singapore Public Primary Care Institution
Real Time Research in a Singapore Public Primary Care InstitutionReal Time Research in a Singapore Public Primary Care Institution
Real Time Research in a Singapore Public Primary Care InstitutionZoe Mitchell
 
Towards Patient-Centred Care
Towards Patient-Centred CareTowards Patient-Centred Care
Towards Patient-Centred CareZoe Mitchell
 
PRO/CON DEBATE: PRO To FEV1 or Not
PRO/CON DEBATE: PRO To FEV1 or NotPRO/CON DEBATE: PRO To FEV1 or Not
PRO/CON DEBATE: PRO To FEV1 or NotZoe Mitchell
 
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPD
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPDValidation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPD
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPDZoe Mitchell
 
REG-EAACI Taskforce Report
REG-EAACI Taskforce ReportREG-EAACI Taskforce Report
REG-EAACI Taskforce ReportZoe Mitchell
 
Digital Footprint: A Step in Which Direction?
Digital Footprint: A Step in Which Direction?Digital Footprint: A Step in Which Direction?
Digital Footprint: A Step in Which Direction?Zoe Mitchell
 
REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15Zoe Mitchell
 

Más de Zoe Mitchell (12)

ILD Working Group Meeting
ILD Working Group MeetingILD Working Group Meeting
ILD Working Group Meeting
 
Databases and Coding Validation Working Group Meeting
Databases and Coding Validation Working Group MeetingDatabases and Coding Validation Working Group Meeting
Databases and Coding Validation Working Group Meeting
 
ACOS Working Group Meeting
ACOS Working Group MeetingACOS Working Group Meeting
ACOS Working Group Meeting
 
REG IPF / ILD Working Group Meeting
REG IPF / ILD Working Group MeetingREG IPF / ILD Working Group Meeting
REG IPF / ILD Working Group Meeting
 
Meeting Report ERS 2013
Meeting Report ERS 2013 Meeting Report ERS 2013
Meeting Report ERS 2013
 
Real Time Research in a Singapore Public Primary Care Institution
Real Time Research in a Singapore Public Primary Care InstitutionReal Time Research in a Singapore Public Primary Care Institution
Real Time Research in a Singapore Public Primary Care Institution
 
Towards Patient-Centred Care
Towards Patient-Centred CareTowards Patient-Centred Care
Towards Patient-Centred Care
 
PRO/CON DEBATE: PRO To FEV1 or Not
PRO/CON DEBATE: PRO To FEV1 or NotPRO/CON DEBATE: PRO To FEV1 or Not
PRO/CON DEBATE: PRO To FEV1 or Not
 
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPD
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPDValidation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPD
Validation of Real-World Thoracic CT Scanes for Quantitative Analysis of COPD
 
REG-EAACI Taskforce Report
REG-EAACI Taskforce ReportREG-EAACI Taskforce Report
REG-EAACI Taskforce Report
 
Digital Footprint: A Step in Which Direction?
Digital Footprint: A Step in Which Direction?Digital Footprint: A Step in Which Direction?
Digital Footprint: A Step in Which Direction?
 
REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15REG PCORI Grant Planning Meeting 26/09/15
REG PCORI Grant Planning Meeting 26/09/15
 

Último

Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxVeereshDemashetti
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUKanhu Charan
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Dr. Dheeraj Kumar
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxAbdirahmanWaseem
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeQuick MedTalk
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, PDr.Shalu Jain
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...Genesis Institute of Pharmacy, Radhanagari.
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyYves Sucaet
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomSudhir Kumar
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdfHongBiThi1
 

Último (20)

Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Reproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptxReproductive and Child Health Services ppt.pptx
Reproductive and Child Health Services ppt.pptx
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders ...
 
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHUTARGET DELINEATION IN CERVIX CANCER BY DR KANHU
TARGET DELINEATION IN CERVIX CANCER BY DR KANHU
 
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
Range of Secondary Electrons and Electron Build-Up: Impact on Scatter in Homo...
 
SMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptxSMA Implementation science seminar (Day 1).pptx
SMA Implementation science seminar (Day 1).pptx
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on timeTracheostomy .pdf ENT by QuickMedTALK. getting things done on time
Tracheostomy .pdf ENT by QuickMedTALK. getting things done on time
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
Ayurveda research in Hypothyroidism, P
Ayurveda  research  in Hypothyroidism, PAyurveda  research  in Hypothyroidism, P
Ayurveda research in Hypothyroidism, P
 
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
HDT Unit 2: Nutraceuticals Global Market Overview And Growth Of Nutraceutical...
 
Explaining "pathology" in digital pathology
Explaining "pathology" in digital pathologyExplaining "pathology" in digital pathology
Explaining "pathology" in digital pathology
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency RoomNeurological Evaluation of Acute Ischemic stroke in Emergency Room
Neurological Evaluation of Acute Ischemic stroke in Emergency Room
 
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
SGK PHÙ PHỔI CẤP ĐHYHN                   .pdfSGK PHÙ PHỔI CẤP ĐHYHN                   .pdf
SGK PHÙ PHỔI CẤP ĐHYHN .pdf
 

Utilising real-world evidence to achieve precision medicine in COPD

  • 1. 19/04/2016 1 Precision medicine: tailoring COPD management to specific patient needs, phenotypespat e t eeds, p e otypes Alan Kaplan MD CCFP(EM) FCFP Chairperson Family Physician Airways Group of Canada Conflicts: Advisory Board or speakers bureau for  Astra Zeneca, Boehringer Ingelheim, Novartis, Takeda,  Merck Frosst, Pfizer, Purdue 1 Objectives • Review current guidelines for COPD pharmacotherapy • Review how to tailor our pharmacotherapy to those who  will best benefit from them – Personalized care vs guideline care oror – How to use guidelines in the patient in front of you • Discuss how to fix it when therapy is perhaps..not as  optimized as it could be! 2 I am not going to talk about • Making an early diagnosis • Smoking cessation • Pulmonary Rehabilitation • Oxygen therapy • End of life therapy in COPD • Multimorbitidity 3 Nice overview to make you consider the individual patient in front of you 4
  • 2. 19/04/2016 2 TREATABLE TRAITS (can coexist) IMP RE C DIAGNOSTIC CRITERIA TREATMENT MAIN EXPECTE D BENEFIT First choice Efficacy Second choice* Airflow limitation +++ +++ FEV1/FVC < 0.7 (or LLN) S Airway smooth muscle contraction ++ +++ BD Reversibility, PEF variability, positive PC20 Maintenance: LABA and/or LAMA Rescue: SABA or SAMA +++ ICS Bronchial Thermoplastya S Loss of elastic recoil (Emphysema ) +++ ++ CT, DLCO, compliance Smoking cessation + LVRS, Lung transplantation, a1anti-trypsin replacement if deficient. Valves, coils S,P Airway mucosal oedema ++ + CT. Spirometry-induced bronchoconstriction. ICS ++ OCS. Anti-IL5, IL13, IL4 E Eosinophilic airway +++ +++ Sputum eos, blood eos, ICS +++ OCS, LTRA, Anti-IgE, Anti- E Table 1. Pulmonary treatable traits of airway diseases 5 Eosinophilic airway inflammation (EAI) Sputum eos, blood eos, FENO, (periostin) ICS OCS, LTRA, Anti IgE, Anti IL5, IL13, IL4 E Chronic bronchitis ++ +++ Cough and sputum 3 months x 2 yrs. (no EAI) Smoking cessation + Carbocysteine, macrolides, roflumilast E Airway bacterial colonization* ++ ++ Sputum culture, quantitative PCR Antibiotics ++ Long-term low dose macrolides, vaccination E/S Bronchiectasis* ++ ++ CT Drainage + Macrolides, Nebulized Antibiotics, Surgery, Vaccination E/S Cough reflex hyper- sensitivity ++ +++ Capsaicin challenge, cough counts, cough questionnaire. Speech and language treatment (63) + Gabapentin (62) . S Pre-capillary pulmonary hypertension* ++ ++ Doppler echocardiography, BNP Right-heart catheterization LTOT ++ NIV Lung transplantation S,E,P Chronic respiratory failure* Arterial hypoxemia +++ +++ PaO2<55 mmHg LTOT ++ P Arterial hypercapnia +++ +++ PaCO2>45 mmHg + NIV Agusti A et al. 2015 TREATABLE TRAITS (can coexist) IMP RE C DIAGNOSTIC CRITERIA TREATMENT MAIN EXPECT ED BENEFIT First choice Efficacy Second choice* Deconditioning + + CPET, 6MWD Exercise, rehabilitation + S,P Obesity + +++ BMI Diet, Physical activity + Medication, Bariatric surgery S,P Cachexia + +++ BMI Diet, Physical activity + S, E OSAS + ++ Questionnaires, PSG CPAP + Weight loss. Mandibular advancement splint S,P Cardiovascular disease ++ +++ EKG, Doppler Echocardiography, BNP ACE inhibitors, diuretics, b-Blockers ++ Surgery S,E,P GERD (64) + ++ GI endoscopy pH PPI, H2 antagonist + Surgery S Table 2. Extra-pulmonary treatable traits of airways diseases 6 GERD (64) GI endoscopy, pH monitoring PPI, H2 antagonist Surgery S Upper airway diseases rhino- sinusitis + ++ History and examination, imaging Topical steroids ++ LTRA, antihistamines, surgery S, E Upper airway diseases Inducible laryngeal obstruction (vocal cord dysfunction) ++ + Fibreoptic laryngoscopy, flow- volume curve, dynamic CT neck Speech pathology therapy (63) ++ Laryngeal botulinum toxin Psychology/psychiatry S Psychiatric disorders: depression ++ ++ Questionnaires, psychologist/liaison psychiatrist assessment CBT, pharmacotherapy ++ S Psychiatric disorders Anxiety: Anxiety/other behavioural aspects including breathing ++ ++ Questionnaires, psychologist/liaison psychiatrist assessment Anxiety management, breathing retraining + Anxiolytic/antidepressant medication, CBT, Psychotherapy S Agusti A et al. 2015 7 8
  • 3. 19/04/2016 3 Let’s deal with two scenarios 1) The patient with recurrent exacerbations 2) The returning patient on therapy 9 Case 1 • 67 year old woman with established COPD • No longer golfing due to dyspnea • On LABA/LAMA plus SABA for breakthrough • FEV1 40% • CAT score 15 • Says, ‘I am doing fine’ • Averages two exacerbations yearly, admitted last year once • You have done all the other little things: CV protection, osteoporosis screening, mood is ok, weight is stable, referred for pulmonary rehabilitation • Is she fine? • How do you decide? 10 What are your options (for exacerbation prevention)? • Add ICS to LABA/LAMA • Change to ICS/LABA plus LAMA • Add Roflumilast to LABA/LAMA f CS/• Add Roflumilast to LAMA plus ICS/LABA 11 Based on combined assessment of airflow limitation, symptoms and exacerbation risk Exacerb cationof ation (FEV1 < 30% predicted) (30% ≤ FEV1 < 50% predicted) GOLD Group C ICS + LABA, or LAMA ICS + LABA +/or LAMA Recommended first choice GOLD Group D ≥2 or ≥1 leading to hospital admission GOLD Grade 4 LAMA + LABA or LAMA + PDE-4i or LABA + PDE-4i ICS + LABA + LAMA or ICS + LABA + PDE-4i or LAMA + LABA or LAMA + PDE-4i Alternative choice Pharmacologic management of COPD GOLD 2015 GOLD Grade 3 12 Risk bationhistory Risk GOLDclassific airflowlimit (50% ≤ FEV1 < 80% predicted) (FEV1 ≥ 80% predicted) LAMA or LABASAMA or SABA p.r.n. GOLD Group A GOLD Group B 1 (not leading to hospital admission) Symptoms CAT ≥10CAT <10 mMRC 01 mMRC ≥2 Breathlessness LAMA or LABA or SABA + SAMA LAMA + LABA GOLD 2015 CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRQoL, health-related quality of life; ICS, inhaled corticosteroids; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; PDE-4i, phosphodiesterase type 4 inhibitor; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist GOLD Grade 2 GOLD Grade 1
  • 4. 19/04/2016 4 CTS/CHEST Guidelines: AECOPD EVEN EASIER, RIGHT? 2014 CHEST-CTS Guideline: Prevention of Acute Exacerbation of Chronic Obstructive Pulmonary Di COPD Exacerbations: Effects of ICS   (ISOLDE ‐ stratified by FEV1) 2.64 1.86 1.722.0 2.5 3.0 * * Placebo r year) Fluticasone 1.24 1.41 1.24 0.0 0.5 1.0 1.5 Burge et al. Br Med J. 2000; 320:1297-1303. FEV1 (litres) Exacerbations (pe 1.25 ‐ 1.54 >1.54<1.25 14 Impact of ICS on survival without re‐ hospitalisation • Alberta • 6,740 patients • Aged > 65 yrs ICS 29% ehospitalisation 1.0 0.9 0 8 Inhaled steroids Sin DD & Tu JV, AJRCCM 2001; 164: 580-584 • ICS group: 29% relative risk reduction for all-cause mortality and 24% for re-hospitalisation Survivalwithoutre Time from discharge (months) 0.8 0.7 0.6 No inhaled steroids 0 2 4 6 8 10 12 15 TORCH: LABA/ICS Significantly Reduced Rate of  Exacerbations Over 3 Years exacerbations/year 1.13 0.97* 0.93* 0.85*†‡ SALM/FP 25% reduction in exacerbations vs. placebo 0.8 1 1.2 LABA: Long-acting beta2-agonist ; ICS: inhaled corticosteroid SALM: salmeterol; FP: fluticasone propionate SALM/FP: salmeterol/fluticasone propionate *P < 0.001 vs. placebo †P =0.002 vs. SALM ‡P = 0.024 vs. FP Meannumberofe 0 0.2 0.4 0.6 Placebo SALM FP SALM/FP Treatment Adapted from Calverley PM, et al. N Engl J Med. 2007;356:775-789. 16
  • 5. 19/04/2016 5 0.4 0.3 0.2 erbations/patient TIO + budesonide/formoterol 320/9 µg BID TIO + placebo CLIMB: ICS/LABA + Tiotropium Reduced Severe Exacerbations at 3 Months A reduction in rate of exacerbation by 62% 17 0.1 0.0 0 15 30 45 60 75 90 Days since randomisation Exac Ratio: 0.38 (95% CI: 0.25–0.57) P < 0.001* *Poisson regression adjusted for overdispersionSevere exacerbations were defined as worsening of COPD leading to treatment with systemic steroids (oral or parenteral) and/or hospitalization/emergency room visits. Welte T, et al. Am J Respir Crit Care Med 2009; doi:10.1164/rccm.200904-0492OC. Goal: prevent exacerbations Goal: decrease symptoms Bronchodilate!!! Cough and Sputum: One of the Susceptible Phenotypes for COPD Exacerbators * * p<0.0001 erbationsPerYear 19 Percentwith≥2Exac Burgel P-R, et al. Chest. 2009;135:975-982. How about Roflumilast Proportion of Patients with a Moderate or Severe Exacerbation sal or tio + placebo sal or tio + roflumilast 500 µg 20 16 12 acerbation (%) 16 1111 18 Exacerbation rates were based on a Poisson regression model; Risk ratios (RiR) were based on a log binomial regression model Fabbri LM, et al. Lancet. 2009 Aug 29;374(9691):695-703. n = 83/467 n = 51/466 n = 58/372 n = 42/371 RiR = 0.60 (95% CI 0.43, 0.82) p = 0.0015 RiR = 0.73 (95% CI 0.51, 1.05) p = 0.0867 Salmeterol study Tiotropium study 12 8 4 0 n=83/467 n=51/466 n=58/372 n=42/371 Patients with an exa 1111
  • 6. 19/04/2016 6 0.60 1.0 REACT – reduction in rate of severe exacerbations (i.e. events leading to hospitalization and/or death) Adding Roflumilast to triple therapy ∆ = -24.3% Rate ratio = 0.757 CI: 0.601, 0.952 p=0.018 All patients Patients with a prior hospitalization Patients without a prior hospitalization ∆ = -34.9% Rate ratio = 0.651 CI: 0.477, 0.887 p=0.007 ∆ = -7.6% Rate ratio = 0.924 CI: 0.669, 1.278 p=0.634 cerbationsper eryear 0.32 0.18 0.24 0.39 0.17 0 0.5 N=319      N=322 N=647     N=647 Analysis of rate of severe exacerbations per patient per year using a negative binomial regression model, ITT Martinez FJ, et al. Presented at ERS 2015; OA482 Martinez FJ, et al. Lancet 2015;385:857-66. Placebo + LABA/ICS Roflumilast + LABA/ICS N=966 N=969 NNT = 12.5 NNT = 4.8 NNT = 100.0 Meanrateofexac patientpe Roflumilast: Incidence of AEs ( 2.5%)* Adverse Event AURA/HERMES 1 year HELIOS 6 months Roflumilast (n=1547) Placebo (n=1545) Tiotropium + Roflumilast (n=374) Tiotropium + Placebo (n=369) COPD 10% 13% 16% 19% Weight loss 10% 3% 6% <1% Diarrhea 8% 3% 9% <1% Nasopharyngiti s 6% 6% 6% 5% Nausea 4% 2% 3% 1% Bronchitis 4% 4% 2% 3% Headache 3% 2% 2% 0% Back pain 3% 2% 2% 1% *Independent of investigator causality assessments Calverley PM, et al. Lancet. 2009 Aug 29; 374(9691):685-94. Fabbri LM, et al. Lancet. 2009 Aug 29;374(9691):695-703. So, where are we? • Tailor our therapy to our patient • Bronchodilate aggressively to improve functionality • Anti-inflammatory to help prevent exacerbations • Reassess over time • But what is the real life situation? • In Canada/ most of the world, there are a large number of patients with COPD currently on ICS! 23 ICS use in COPD (Real life data in Canada) Reza Maleki-Yazdi M. et al. ATS 2015, P551 024
  • 7. 19/04/2016 7 So, where are we? • Tailor our therapy to our patient • Bronchodilate aggressively to improve functionality • Anti-inflammatory to help prevent exacerbations • Reassess over time • But what is the real life situation? • In Canada/ most of the world, there are a large number of patients with COPD currently on ICS! • Do ICS decrease COPD mortality?? 25 TORCH: All‐Cause Mortality at 3 Years 18 16 14 12 10 ofdeath(%) SALM/FP 17.5% reduction in mortality vs placebo (p=0.052) No significant difference of mortality with ICS SALM = salmeterol FP = fluticasone propionate SALM/FP = salmeterol/fluticasone propionate 8 6 4 2 0 Time to death (weeks) Probabilityo 0 12 24 36 48 60 72 84 96 108 120 132 144 156 Vertical bars are standard errors SALM SALM/FP FP Placebo Adapted from Calverley PMA, et al. N Engl J Med. 2007;356. 26 Case 2 • A different patient with COPD • FEV1 45% • No exacerbations needing steroids in five years • Couple of antibiotics for Sinusitis, did not move into their chest • CAT score: 18 • On triple therapy: ICS/LABA and LAMA • Does this patient need their ICS? • Can you stop it? • If so, how to stop it? 28
  • 8. 19/04/2016 8 Side effects of ICS in COPD  and type of evidence  Randomised controlled trial Observational study Systematic review Pneumonia X X X Tuberculosis X Bone fracture (no effect on fracture risk) X X fracture risk) Skin thinning/ easy bruising X Cataract X Diabetes X Oropharyngeal candidiasis X X X Price D. Prim Care Respir J 2013; 22: 92-100. 29 Risk of Diabetes1 Risk of Bone Fracture2 3.5 3.0 2.5 atio 2 Loke YK et al Thorax 2011;66(8):699-708 31 Meta-analysis of studies including 17,513 patients with COPD 2.0 1.5 1.0 0.5 0 250 500 750 10001250 1500 17502000 Daily dose in fluticasone equivalents (mcg) Rate Ra 1. Suissa S, et al.: Am J Med 2010; 123(11):1001‐6.  Several recent studies with varying populations/design have compared bronchodilator therapy with LABA/ICS OPTIMO – in patients with moderate COPD (FEV1 >50% predicted) and <2 exacerbations, currently maintained on ICS for past year, ICS withdrawal was not associated with increased exacerbations, difference in lung function or CAT (Rossi, et. al. Resp Res 2014; 6 month “real-world” study of ICS withdrawal - decision to maintain or withdraw ICS at discretion of clinician) INSTEAD – in patients with moderate COPD (FEV1 40-80% predicted) and no recent exacerbations, maintained on SFC for > 3 months, indacaterol was NI on lung function (t h FEV1 9 l) d id f i d b ti(trough FEV1 = -9 ml) and no evidence of increased exacerbations (Rossi, et. al. ERJ 2014; 26 week randomized, parallel, DB study of withdrawal of ICS from SFC 500/50 to Indacaterol 150 µg) ILLUMINATE - in patients with moderate COPD (FEV1 40-80% predicted) and no recent exacerbations, QVA (LABA/LAMA) improved lung function (FEV1AUC0-12 138ml, p<0.001) and TDI vs LABA/ICS (Vogelmeier, et. al. Lancet Resp Med 2012, 26 week randomized, parallel, DB study of QVA149 vs SFC 500/50) LANTERN- in symptomatic patients with moderate to severe COPD (FEV1 30-80) and 0-1 exacerbations on SFC changed to QVA (LABA/LAMA) showed improved lung function (FEV1 AUC0-4h 122 mL; p<0.001) and decreased exacerbations (HR 0.65 p .028) (Zhong et al. Int J COPD 2015. A randomized control study of QVA 149 vs SFC)32
  • 9. 19/04/2016 9 Wisdom Estimated probability of moderate or severe COPD exacerbation 0.6 0.4 tedprobability 0.3 0.5 Hazard ratio, 1.06 (95% CI, 0.94–1.19) P=0.35 by Wald’s chi-squared test 1243 1242 1059 1090 927 965 827 825 763 740 646 646 694 688 615 607 581 570 14 19 No. at risk ICS ICS withdrawal 0.2 0.0 0 6 12 18 24 30 36 42 48 54 ICS ICS withdrawal Estima Time to events (weeks) 0.1 Magnussen H et al. N Engl J Med DOI 10.1056/NEJMoal407154 -20 0 0 6 12 18 52 SE)change FEV1(mL) Week ICS 38 mL 100 µg BID 0 µg (placebo)250 µg BID Mean change from baseline in lung function: FEV1 ICS withdrawal -80 -60 -40 Adjustedmean(S frombaselinein **p<0.01; ***p<0.0001 vs ICS; restricted maximum likelihood repeated measures model; baseline values 970 mL for ICS, 981 mL for ICS withdrawal ICS ICS withdrawal *** ** 1223 1218 1135 1135 1114 1092 1077 1058 970 935 n ICS withdrawal ICS 43 mL Magnussen H et al. N Engl J Med DOI 10.1056/NEJMoal407154 Time to first severe and any severity on- treatment COPD exacerbation 0.975 1.202 1.482 Time to first severe COPD exacerbation 36 Hazard ratio Time to first COPD exacerbation (any severity) On-treatment exacerbations assessed; hazard ratio from Cox proportional hazards model adjusted for baseline FEV1 Favours ICSFavours withdrawal Magnussen H et al. N Engl J Med DOI 10.1056/NEJMoal407154
  • 10. 19/04/2016 10 So, definitely not with patients with Asthma-COPD Overlap Syndrome (ACOS) • Older patients (≥45 years) with chronic airflow limitation • Bronchodilator response (>12%, >400 mL) but not fully reversiblebut not fully reversible • Family or personal history of asthma, atopy or allergic rhinitis • Asthmatic with smoking history or biomass exposure Dr. Don Sin. 16th Annual Respiratory Medicine Update, 8 February 2014. Papaiwannou A, et al. J Thoracic Dis 2014;6(S1):S146-S151. FLAME: QVA149 vs.SFC in terms of rate of all COPD exacerbations (mild/moderate/severe) for 52 weeks • moderate to very severe COPD (GOLD 2011), • a smoking history of ≥10 pack-years, • one or more 1 COPD exacerbation requiring systemic corticosteroids and/or antibiotics in the previous 12 months.38 Initial results: press release 39 Does it depend on the eosinophil?
  • 11. 19/04/2016 11 Changes in post- bronchodilator FEV1 in patients with or without sputum eosinophilia EV1(L) 0.10 *,# 0.15 *,# With sputum eosinophilia Without sputum eosinophilia SputumSputum eosinophiliaeosinophilia and responseand response toto budesonidebudesonide in COPD:in COPD: ICSICS worksworks in COPDin COPD withwith sputumsputum eosinophiliaeosinophilia Leigh et al. ERJ 2006;27:964-971 ∆Post-BDFE -0.05 0.05 0.00 PrednisoneBudesonidePlacebo *p<0.05 within group (sputum eosinophilia) vs placebo #p<0.05 between groups If blood eosinophils predict response to ICS, what is the appropriate cutoff? 42 Do eosinophils predict response to ICS beyond exacerbations? Chiesi data: 43 | QVA Update | Robert Fogel | Canada Advisory Board, Sep 26, 2015 |Business Use Only | Material ID Code:
  • 12. 19/04/2016 12 Taking patients off ICS in COPD 45 Risk of recurrent pneumonia rises with current ICS use,  not linked to past ICS use 46 Eurich DT et al. Clin Infect Dis. 2013; 57 (8): 1138-1144 Discontinuation of ICS reduced the risk of pneumonia associated with long-term ICS use Risk of pneumonia following ICS withdrawal Retrospective analysis using the Quebec health insurance databases for COPD patients discontinued from ICS during 1990-2005 (n=103,386). COPD=chronic obstructive pulmonary disease; ICS=inhaled corticosteroid. Suissa S et al. Chest. 2015;148(5):1177-1183.
  • 13. 19/04/2016 13 Are they eligible for ICS withdrawal? If no reason they should stay on ICS... PREDICTIVE ACCURACY OF PREDICTING ≥ 2 EXACERBATIONS IN OUTCOME YEAR Daryl Freeman GP Mundesley North Norfolk,  Clinical Director East of England SCN  (respiratory). IMPACT study REG sponsored Odds ratios for ≥ 2 exacerbations from logistic regression in patients with CAT score available (n=3,713) total population n=3,713 Odds Ratio (95% CI) P-value Baseline number of exacerbations 1.79 (1.68-1.92) <10-10 19% of patients had ≥ 2 exacerbations FEV1 % predicted per 10% lower 1.06 (1.01-1.12) 0.02 Female gender 1.32 (1.10-1.58) 0.003 Asthma record ever 1.19 (1.00-1.43) 0.052 Nasal polyps ever 2.02 (1.24-3.29) 0.005 Eosinophilia (≥ 0.5 x 10-9 ) in non-smokers 1.42 (1.03-1.97) 0.03 CAT score per 10 units higher 1.26 (1.14-1.40) 1 x 10--5
  • 14. 19/04/2016 14 There may be other factors we can use • To predict exacerbations • To predict response to ICS • To predict response to stopping ICS o New REG study being done on those with COPD whoy g have stopped ICS and outcomes o -unfortunately, numbers are small in GPRD currently. What does a personalized COPD assessment look like? • Symptoms: CAT, MRC, CCQ • Are they at risk of attack? – Previous exacerbations, chronic bronchitis, lung function, GERD • Lung function • Still smoking? • Is there Asthma there? Allergy, rhinitis hx? • Comorbidities: GERD, Depression, Osteoporosis, Anxiety • Adherence – Refill prescription rates • Inhaler technique • Pulmonary Rehabilitation • Biomarkers: eosinophils (blood and sputum), FENO? • Biologics..coming? • Self management plan • Pathway to further treatments: oxygen, LVRT, transplant.EOL care! 54 Thank you for any thoughts you have about this study! www fpagc comwww.fpagc.com for4kids@gmail.com